CTLA4 and melanoma: In contrast to the described lack of synergism when lactate production is targeted using a pharmacological approach, there has been reported synergism with diclofenac-mediated inhibition of lactate transporters MCT1 and MCT4, present both on tumor cells and T cells, in combination with anti-PD1 and anti-CTLA4 therapy in melanoma xenografts [68].